News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Home
| Debio 0719 |
|
Debio 0719 is a selective inhibitor of type 1 lysophosphatidic acid receptor (LPA1) and type 3 (LPA3). LPA1 plays a key role in osteolytic bone damage induced by breast tumour metastasis. Preclinical investigations demonstrated that blockage of LPA1 by use of Debio 0719 led to a reduction in osteolytic lesions and tumour expansion.
Press Releases30-Jan-2007
Publications23-Feb-2009 15-Aug-2008 20-Jun-2006 23-Apr-2004 20-Feb-2004 -> All Publications |